ArticleTranslational cancer research2025
The role of YTHDF1 in the diagnosis and prognosis of lung adenocarcinoma and its inhibitor LY-411575 in the targeted intervention of lung adenocarcinoma growth.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: YTHDF1, a regulator of N6-methyladenosine (m6A) modification, participates in regulating the pathological mechanism of cancer, but its role in lung adenocarcinoma (LUAD) remains in need of deeper elucidation. This study aimed to uncover potential molecular characteristics of YTHDF1 in LUAD, establishing a conceptual foundation for disease management. Methods: YTHDF1 expression was analyzed in LUAD using The Cancer Genome Atlas (TCGA) data, quantitative real-time polymerase chain reaction (qRT-PCR), and Western blotting. A competitive endogenous RNA (ceRNA) network was established to explore molecular interactions, and LUAD was categorized based on YTHDF1 expression levels. Survival rates and immune cell infiltration were compared between categories. Genes related to YTHDF1 were identified based on weighted gene co-expression network analysis (WGCNA), and related functional enrichment analysis was performed. Chemotherapy drug sensitivity against YTHDF1 was predicted using the pRRophetic algorithm and the Genomics of Drug Sensitivity in Cancer (GDSC) data. YTHDF1-specific small molecule inhibitors were screened, and their effects on LUAD progression were analyzed Results: Results showed YTHDF1 was up-regulated in LUAD and may be a new diagnostic biomarker of LUAD. Increased YTHDF1 expression was related to poor prognosis and immune dysregulation in LUAD. The study identified 130 co-expressed genes and 37 chemotherapy drugs associated with YTHDF1 expression. The small molecule inhibitor LY-411575 targeting YTHDF1 could inhibit the growth of LUAD cells. Conclusions: Our study indicates that elevated expression of YTHDF1 is a predictor of poor prognosis in patients with LUAD and may serve as a potential diagnostic biomarker and therapeutic target for this disease. In addition, we identified LY-411575 as a YTHDF1 inhibitor that effectively inhibits the proliferation of LUAD cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.